Agenus, made the following post on LinkedIn:
“Agenus completed the planned patient enrollment of its Phase 2 clinical trial evaluating investigational agents botensilimab (BOT) and balstilimab (BAL) in advanced colorectal cancer.”
For details click here.
Source: Agenus/LinkedIn